Advanced Pathology Laboratory LLC
Advanced Pathology Laboratory LLC was paid $4K by Medicaid between Oct 2018 and Oct 2024, across 16 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 48% of everything it billed.
BROOKLYN, NY 11206
Next to other Clinical Pathology/Laboratory Medicine Physician providers in New York
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15 | $18.72 | |
| 2023 | 30 | $0.00 | |
| 2024incomplete | 303 | $4K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 48% | 93 | 55 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 30% | 19 | 19 | $1K |
| 87529 | 4.7% | 14 | 14 | $182.46 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.3% | 14 | 14 | $91.23 |
| 87640 | 2.3% | 19 | 19 | $91.23 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.3% | 19 | 19 | $91.23 |
| 87500 | 2.3% | 13 | 13 | $91.23 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.3% | 14 | 14 | $91.23 |
| 87641 | 2.3% | 16 | 16 | $91.23 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.3% | 14 | 14 | $91.23 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 29 | 28 | $18.72 |
| 81227 | 0% | 15 | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Etl- Northeast LLC | Doraville, GA | $3.89M |
| Emergent Testing Lab LLC | Brookhaven, GA | $1.94M |
| Emergent Testing LLC | Atlanta, GA | $2K |
| Emergent Testing of Texas PLLC | Houston, TX | $913.25 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.